Efficiency of Conditionally Attenuated Salmonella enterica Serovar Typhimurium in Bacterium-Mediated Tumor Therapy.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractIncreasing numbers of cancer cases generate a great urge for new treatment options. Applying bacteria like Salmonella enterica serovar Typhimurium for cancer therapy represents an intensively explored option. These bacteria have been shown not only to colonize solid tumors but also to exhibit an intrinsic antitumor effect. In addition, they could serve as tumor-targeting vectors for therapeutic molecules. However, the pathogenic S. Typhimurium strains used for tumor therapy need to be attenuated for safe application. Here, lipopolysaccharide (LPS) deletion mutants (ΔrfaL, ΔrfaG, ΔrfaH, ΔrfaD, ΔrfaP, and ΔmsbB mutants) of Salmonella were investigated for efficiency in tumor therapy. Of such variants, the ΔrfaD and ΔrfaG deep rough mutants exhibited the best tumor specificity and lowest pathogenicity. However, the intrinsic antitumor effect was found to be weak. To overcome this limitation, conditional attenuation was tested by complementing the mutants with an inducible arabinose promoter. The chromosomal integration of the respective LPS biosynthesis genes into the araBAD locus exhibited the best balance of attenuation and therapeutic benefit. Thus, the present study establishes a basis for the development of an applicably cancer therapeutic bacterium.
CitationEfficiency of Conditionally Attenuated Salmonella enterica Serovar Typhimurium in Bacterium-Mediated Tumor Therapy. 2015, 6 (2): MBio
AffiliationHelmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
- Optimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy.
- Authors: Felgner S, Kocijancic D, Frahm M, Curtiss R 3rd, Erhardt M, Weiss S
- Issue date: 2016
- aroA-Deficient Salmonella enterica Serovar Typhimurium Is More Than a Metabolically Attenuated Mutant.
- Authors: Felgner S, Frahm M, Kocijancic D, Rohde M, Eckweiler D, Bielecka A, Bueno E, Cava F, Abraham WR, Curtiss R 3rd, Häussler S, Erhardt M, Weiss S
- Issue date: 2016 Sep 6
- Down-regulation of key virulence factors makes the Salmonella enterica serovar Typhimurium rfaH mutant a promising live-attenuated vaccine candidate.
- Authors: Nagy G, Danino V, Dobrindt U, Pallen M, Chaudhuri R, Emödy L, Hinton JC, Hacker J
- Issue date: 2006 Oct
- Spatial segregation of virulence gene expression during acute enteric infection with Salmonella enterica serovar Typhimurium.
- Authors: Laughlin RC, Knodler LA, Barhoumi R, Payne HR, Wu J, Gomez G, Pugh R, Lawhon SD, Bäumler AJ, Steele-Mortimer O, Adams LG
- Issue date: 2014 Feb 4
- Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar typhimurium.
- Authors: Kong Q, Yang J, Liu Q, Alamuri P, Roland KL, Curtiss R 3rd
- Issue date: 2011 Oct